Biosimilars Or Biobetters: Make Your Decisions Wisely

There is an increasing interest in biosimilars and biobetters, with the total number of reported development candidates equaling the number of innovative development compounds. Even assuming attrition in development, the biosimilars market will suffer from significant competition in the future. The present article builds on a financial modeling approach that takes into account development cost and risk and minimum required sales to yield a robustly positive financial value. In reference to the commercial success of the originator, such models can facilitate portfolio decisions. Predictive success criteria for biosimilars on the one hand and biobetters on the other hand are presented.